¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Other problems related to life-management difficulty"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • age-related cognitive decline
    ³ªÀ̰ü·ÃÀÎÁöÀúÇÏ
  • age-related degeneration
    ³ªÀ̰ü·Ãº¯¼º, ³ë³â±âº¯¼º
  • breathing related sleep disorder
    È£Èí°ü·Ã¼ö¸éÀå¾Ö
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • related
    ±ÙÄ£-
  • stress-related disorder
    ½ºÆ®·¹½º°ü·ÃÀå¾Ö
  • sleep-related epilepsy
    ¼ö¸é°ü·Ã°£Áú
  • sleep-related sinus arrest
    ¼ö¸é°ü·Ã±¼¹æ°áÀýÁ¤Áö
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • age-related degeneration
    ³ªÀ̰ü·Ãº¯¼º, ³ë³â±âº¯¼º
  • age-related cognitive decline
    ³ªÀ̰ü·ÃÀÎÁöÀúÇÏ
  • sleep-related sinus arrest
    ¼ö¸é°ü·Ã½ÉÀå¹Úµ¿Á¤Áö
  • breathing related sleep disorder
    È£Èí°ü·Ã¼ö¸éÀå¾Ö
  • diagnosis related group
    À¯»çÁø´Ü±ºÀÇ·áºñÁöºÒ¹ý
  • stress-related disorder
    ½ºÆ®·¹½º°ü·ÃÀå¾Ö
  • tobacco-related disorder
    ´ã¹è°ü·ÃÀå¾Ö
  • sleep-related epilepsy
    ¼ö¸é°ü·Ã°£Áú
  • related
    ±ÙÄ£-
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ARC => AIDS-related complex
    ÈÄõ¼º¸é¿ª°áÇÌÁõ°ü·ÃÁõÈıº
  • ARMD->age-related macular degeneration
    ¿¬·É°ü·ÃȲ¹Ýº¯¼º,³ë³â±âȲ¹Ýº¯¼º
  • AlDS-related complex
    ÈÄõ¼º¸é¿ª°áÇÌÁõ°ü·ÃÁõÈıº
  • D-related antigen
    D-°ü·ÃÇ׿ø
  • REM-sleep-related sinus arrest
    ·½¼ö¸é °ü·Ã ½ÉÀ嵿°áÀý(Ô×Ì¿ï½) Á¤Áö
  • age-related cognitive decline
    ¿¬·É °ü·Ã ÀÎÁö ÀúÇÏ
  • fructose-related disorder
    ÇÁ¶ôÅ佺°ü·ÃÀå¾Ö<--Áúº´>
  • hallucinogen-related disorder
    ȯ°¢Á¦ °ü·ÃÀå¾Ö(º´)(ü³ÊÆð¥Î¼Ö¤î¡äô)
  • polysubstance-related disorder
    º¹ÇÕ¹°Áú°ü·ÃÀå¾Ö(º´)
  • related
    ±ÙÄ£(ÐÎöÑ)ÀÇ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • sibling relational problems
    µ¿±â°£°ü°è¹®Á¦
  • atypical, mixed or other personality
    ºñÁ¤Çü ³»Áö È¥ÀçÇü ¶Ç´Â ±âŸ ÀΰÝ
  • shock and other somatic treatment
    Ãæ°Ý ¹× ±âŸ ½Åüġ·á
  • decannulation difficulty
    ¹ß°üÀå¾Ö
  • dyschezia =defecation difficulty
    ¹èº¯°ï¶õÁõ(¹èÆí°ï³­Áõ).
  • dyschezia =defecation difficulty
    ¹èº¯°ï¶õÁõ(ÛÉøµÍÝÑññø).
  • separation difficulty
    (µ¶¼­)ºÐ¸®°ï¶õ
  • speech difficulty =s. disorder, s. disturbance
    ¾ð¾îÀå¾Ö(åëåÞî¡äô)
  • walking difficulty
    º¸Çà°ï¶õ(ÜÆú¼ÍÝÑñ).
  • walking difficulty
    º¸Çà°ï¶õ(ÜÆú¼ÍÝÑñ)
  • age-related cognitive decline
    ¿¬·É °ü·Ã ÀÎÁö ÀúÇÏ
  • age-related macular degeneration
    ¿¬·É°ü·ÃȲ¹Ýº¯¼º, ³ë³â±âȲ¹Ýº¯¼º
  • antigen, D-related
    D-°ü·ÃÇ׿ø
  • breathing related sleep disorder
    È£Èí°ü·Ã¼ö¸éÀå¾Ö(º´)
  • caffeine - related disorder
    Ä«ÆäÀÎ °ü·ÃÀå¾Ö(º´)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • flow related enhancement
    À¯µ¿°ü·ÃÁõ°­
  • technical difficulty
    ±â¼úÀû°ï¶õ
  • urinary difficulty
    ´¢·ÎÀå¾Ö
  • voiding difficulty
    ¹è´¢Àå¾Ö
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AODP alcohol and other drug problems
DIB diagnostic interview for borderlines; difficulty in breathing; disability insurance benefits; dot im...
ICD I-cell disease; immune complex disease; implantable cardioverter defibrillator; impulse-control diso...
ICD-10 International Statistical Classification of Diseases and Health-related Problems, 10th revision
ARC accelerating rate calorimetry; acquired immunodeficiency syndrome-related complex; active renin conc...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DRP Drug Related Problems
ICHPPC International Classification of Health Problems in Primary Care
IIP Inventory of Interpersonal Problems
DRO Differential Reinforcement of Other Behaviour
MOTT Mycobacteria Other Than Tuberculosis
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • Z73.8
    Other problems related to life-management difficulty
    ±âŸ »ýȰ-°ü¸® ¾î·Á¿ò¿¡ °ü·ÃµÈ ¹®Á¦
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • primary emotional difficulty
    ¿ø¹ß¼º Á¤¼­ Àå¾Ö
  • speech difficulty
    ¹ßÀ½ Àå¾Ö, ¾ð¾î Àå¾Ö
    µ¿ÀǾî=s
  • walking difficulty
    º¸Çà Àå¾Ö
    ¾ç´Ù¸®¿¡ üÁßÀ» ½Æ°í ÀϾ ½Åü¸¦ À̵¿½ÃŰ´Â º¸ÇàÀÌ ÀüÇô ºÒ°¡´ÉÇϰųª °ï¶õÇÑ »óÅÂ. ¼ºÀÎÀÇ °æ¿ì¿¡´Â »À, °üÀýÀÇ Áß´ëÇÑ ¿Ü»óÀ̳ª ¸¸¼º°üÀý·ù¸ÓƼÁòÀ» ºñ·ÔÇÏ¿©, ³úÇ÷°ü Àå¾Ö¿¡ ÀÇÇÑ ¹Ý½Å¸¶ºñ, ô¼ö¼Õ»ó, ÆÄŲ½¼ ÁõÈıº, ±ÙÀ§Ã༺ Ãø»ö°æÈ­Áõ µîÀÌ ¿øÀÎÀÌ µÈ´Ù. ¾î¸°ÀÌÀÇ °æ¿ì´Â ½ÉÇÑ Á¤½Å Áöü, ³ú¼º ¸¶ºñ, ÁøÇ༺ ±ÙÀ§ÃàÁõ, ÁøÇ༺ ±Ùµð½ºÆ®·ÎÇÇ µî¿¡ ÀÇÇÑ °ÍÀÌ ÀÖ´Ù. ÇѶ§´Â ¼±Ãµ¼º °í°üÀý Å»±¸¿¡ ÀÇÇÑ º¸ÇàÀå¾Ö¸¦ º¼ ¼ö ÀÖ¾úÀ¸³ª, ¿äÁîÀ½¿¡´Â Á¶±âÁø´Ü, Á¶±âÄ¡·á·Î °ÅÀÇ º¼ ¼ö ¾ø°Ô µÇ¾ú´Ù. ¹ßÀ» ¶¥¿¡ ²ô´Â °Íó·³ °È´Â Àý¶Ò°Å¸²Àº º¸ÇàÀÌ»óÀ̶ó ÇÏ¿©, º¸ÇàÀå¾Ö¿Í´Â º°µµ·Î ´Ù·ç¾îÁöÁö¸¸, ±× ¿øÀΰú Á¤µµ¿¡ µû¶ó¼­´Â ¡®º¸Çà°ï¶õ¡¯À¸·Î ºÐ·ùµÈ´Ù. Àý¶Ò°Å¸²Àº º¸ÇàÀº °¡´ÉÇÏÁö¸¸ ±× °ÉÀ½°ÉÀ̰¡ Á¤»óÀÌ ¾Æ´Ñ °ÍÀ¸·Î, ¿©±â¿¡´Â ¿©·¯ Á¾·ù°¡ ÀÖ´Ù. Á°ñ½Å°æÅë µîÀÇ ¾ÆÇÄÀ» °æ°¨½Ã۱â À§ÇÏ¿© ¹ßÀ» ²ô´Â ȸÇÇÆÄÇà, ¼±Ãµ¼º °üÀý Å»±¸ µî¿¡¼­ º¼ ¼ö ÀÖ´Â °ñ¹ÝÀÌ ³»·Á¿Í¼­ °ÉÀ» ¶§¸¶´Ù ȯºÎ ÂÊÀÇ ¾î±ú°¡ ½ÉÇÏ°Ô ¿À¸£³»¸®´Â Ãß¶ô¼º ÆÄÇà, ÇÏÁöÀÇ À̿ϼº ½Å°æ¸¶ºñ ¶§¹®¿¡ ´ëÅðºÎ¸¦ ¿Ã¸± ¼ö ¾ø¾î¼­ ¹ßÀ» ²ô´Â ¸¶ºñ¼º ÆÄÇà, ³úÁ¹Áß ÈÄÀÇ ¹Ý½Å¸¶ºñ³ª ôÃß Á¾¾ç µîÀÇ Ãßü·Î Àå¾Ö¿¡ ÀÇÇÑ ÇÏÁö ÀüüÀÇ ±Ù±äÀå ¶§¹®¿¡, Á¼Àº º¸ÆøÀ¸·Î ¾ÕÀ¸·Î ¾²·¯Áú µíÀÌ ¹ßÀ» ²ô´Â °æ¼º ÆÄÇàÀ» ºñ·ÔÇÏ¿©, °üÀý °­Á÷À̳ª ±¸·çº´ ¿Ü¿¡ ÇÏÁöÀÇ µ¿¸ÆÇùÂø¿¡ ÀÇÇÑ °£Ç漺 ÆÄÇàÀ̳ª, ´Ù¹ß¼º °æÈ­Áõ, ÁøÇ༺ ¸¶ºñ µî¿¡¼­µµ Àϰú¼º ÆÄÇàÀ» º¼ ¼ö ÀÖ´Ù.
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • other abnormality
    ±âŸ ÀÌ»ó
  • other craniofacial disorder
    ´Ù¸¥ µÎ°³ ¾È¸é Àå¾Ö
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • other mycoses
    ±âŸ Áø±ÕÁõ
  • age-related cognitive decline
    ¿¬·É °ü·Ã ÀÎÁö ÀúÇÏ
  • AIDS related complex
    AIDS °ü·Ã º¹ÇÕÁõ, ÈÄõ¼º ¸é¿ª °áÇÌÁõ°ú ¿¬°üµÈ Áúȯ, ÈÄõ¼º ¸é¿ª °áÇÌÁõ-°ü·Ã º¹ÇÕü, ÈÄõ¼º ¸é¿ª °áÇÌÁõ °ü·Ã º¹ÇÕ ¹ÝÀÀ
  • dynorphin-related peptide
    ´ÙÀ̳îÇÉ °ü·Ã ÆéƼµå
  • pain-related disability
    µ¿Åë°ú °ü·ÃµÈ Àå¾Ö
  • parathyroid hormone-related peptide
    ºÎ°©»ó¼± È£¸£¸ó ¿¬°ü ÆéŸÀ̵å
  • polysubstance-related disorder
    º¹ÇÕ ¹°Áú °ü·Ã Àå¾Öº´
  • related
    ±ÙÄ£ÀÇ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
difficulty Origin: L. Difficultas, fr. Difficilis difficult; dif- = dis- + facilis easy: cf. F. Difficulte. See Facile.
1. The state of being difficult, or hard to do; hardness; arduousness; opposed to easiness or facility; as, the difficulty of a task or enterprise; a work of difficulty. "Not being able to promote them [the interests of life] on account of the difficulty of the region." (James Byrne)
2. Something difficult; a thing hard to do or to understand; that which occasions labour or perplexity, and requires skill perseverance to overcome, solve, or achieve; a hard enterprise; an obstacle; an impediment; as, the difficulties of a science; difficulties in theology. "They lie under some difficulties by reason of the emperor's displeasure." (Addison)
3. A controversy; a falling out; a disagreement; an objection; a cavil. "Measures for terminating all local difficulties." (Bancroft)
4. Embarrassment of affairs, especially financial affairs; usually in the plural; as, to be in difficulties. "In days of difficulty and pressure." (Tennyson)
Synonym: Impediment, obstacle, obstruction, embarrassment, perplexity, exigency, distress, trouble, trial, objection, cavil. See Impediment.
Source: Websters Dictionary
(01 Mar 1998)
social problems Situations affecting a significant number of people, that are believed to be sources of difficulty or threaten the stability of the community, and that require programs of amelioration.
(12 Dec 1998)
International Classification of Health Problems in Primary Care A classification of diseases, conditions and problems arranged for use in primary care where diagnostic precision is seldom possible.
(05 Mar 2000)
other-directed Pertaining to a person readily influenced by the attitudes of others.
(05 Mar 2000)
transferases (other substituted phosphate groups) <enzyme> A class of enzymes that transfers substituted phosphate groups.
Registry number: EC 2.7.8
(12 Dec 1998)
adhesion-related kinase <chemical> New member of the immunoglobulin superfamily with 2 immunoglobulin-like domains
Synonym: ark protein, ark receptor tyrosine kinase
(26 Jun 1999)
age-related macular degeneration A common macular degeneration beginning with drusen of the macula and pigment disruption and sometimes leading to severe loss of central vision.
(05 Mar 2000)
aids-related complex A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating aids-related complex (arc) from aids include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in aids; follicular or mixed hyperplasia in arc lymph nodes, leading to lymphocyte degeneration and depletion more typical of aids; evolving succession of histopathological lesions such as localization of kaposi's sarcoma, signaling the transition to the full-blown aids.
(12 Dec 1998)
aids-related opportunistic infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include pneumocystis carinii pneumonia, kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with mycobacterium avium complex, microsporidium, and cytomegalovirus.
(12 Dec 1998)
AIDS-related virus An obsolete term for human immunodeficiency virus.
(05 Mar 2000)
alcohol-related disorders Mental disorders related or resulting from abuse or mis-use of alcohol.
(12 Dec 1998)
amphetamine-related disorders Disorders related or resulting from use of amphetamines.
(12 Dec 1998)
angiotensin-related carboxypeptidase <enzyme> Rat and bovine brain synaptosomal enzyme can hydrolyze angiotensin I to des-leu angiotensin I, but no further
Registry number: EC 3.4.-
Synonym: angiotensin-specific carboxypeptidase
(26 Jun 1999)
calcitonin gene-related peptide <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response.
It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene.
The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion.
Acronym: CGRP
(05 May 2002)
MAK-related kinase <enzyme> A cdc2-related serine/threonine kinase; shows 87% idnetity to the male-germ cell associated kinase (mak); mw 66 kD; genbank d26178
Registry number: EC 2.7.10.-
Synonym: mrk kinase
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • difficulty
    °ï¶õ,ºÒÈ­,³­±¹
  • difficulty
    °ï¶õ;³­±¹;ÁöÀå;ÀÌÀÇ;³íÀï;±Ã¹Ú
  • related
    °ü°è°¡ ÀÖ´Â
  • Earnings Related Supplement
    (¿µ)º¸Çè ±ÞºÎ±Ý(¿µ±¹ÀÇ »çȸº¸ÀåÁ¦µµ¿¡¼­ 6°³¿ù°£ ½Ç¾÷ÀÚ(ȯÀÚ)¿¡°Ô Àü³âµµ ¼Òµæ¿¡ µû¶ó Áö±ÞµÊ)
  • related
    °ü°è°¡ ÀÖ´Â;°ü·ÃµÈ;Ä£Á·ÀÇ;µ¿Á·ÀÇ
  • related key
    (ÁÖÀ½ µî°ú °¡±î¿î °ü°è°¡ ÀÖ´Â)±ÙÄ£(°ü°è)Á¶
  • each other
    ¼­·Î
  • in some way or other
    ¾î¶»°Ô ÇØ¼­µçÁö
  • other
    ±×¹ÛÀÇ
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • t'other
    ¶Ç Çϳª
  • A.N. Other
    ÀÍ¸í¾¾;¼±¼ö ¹ÌÁ¤
  • other
    µý;´Ù¸¥;´ÙÀ½ÀÇ;³ª¸ÓÁöÀÇ;every ~ Çϳª°É·¯;none ~ than ´Ù¸§ ¾Æ´Ñ;the ~ day(night)ÀÏÀü(¿äÀü³¯ ¹ã)¿¡;the ~ party »ó´ë¹æ;the ~ side (¹Ì±¹¿¡¼­ º») À¯·´;the ~ world ³»¼¼;Àú½Â
  • other
    ±×·¸Áö ¾Ê°í;µý ¹æ¹ýÀ¸·Î
  • other
    µý °Í(»ç¶÷);´Ù¸¥ Çϳª;³ª¸ÓÁö °Í;of all ~s ¸ðµç °Í(»ç¶÷)Áß¿¡¼­ ƯÈ÷;some ... or ~ ¹«¾ð(´©±º,¾îµò)°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á